Alan Buckler biography
Dr. Alan J. Buckler, Ph.D. is Chief Scientific Officer of the company since November 2016. Prior to joining us, Dr. Buckler served as Vice President, Cell and Protein Sciences, at Biogen Inc. from 2014 to 2016. From 2005 to 2014, Dr. Buckler served as Director, Developmental and Molecular Pathways in the Novartis Institutes for Biomedical Research. Prior to Novartis, Dr. Buckler served as the Chief Scientific Officer of Ardais Corporation from 1999 to 2004 and as Vice President of Molecular Genetics at Sequana Therapeutics/Axys Pharmaceuticals from 1996 to 1999. Prior to joining the private sector, Dr. Buckler served on the Neurology faculty of Massachusetts General Hospital and Harvard Medical School from 1991 to 1996. Dr. Buckler received his Ph.D. in Microbiology from the Boston University School of Medicine, and completed his post-doctoral training at the Center for Cancer Research, Massachusetts Institute of Technology. He also holds an A.B. in Biology from the University of Chicago.
What is the salary of Alan Buckler?
As the Chief Scientific Officer of Scholar Rock Corp, the total compensation of Alan Buckler at Scholar Rock Corp is $1,093,970. There are 2 executives at Scholar Rock Corp getting paid more, with Dr. Nagesh K. Mahanthappa MBA, Ph.D. having the highest compensation of $1,372,681.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
How old is Alan Buckler?
Alan Buckler is 60, he's been the Chief Scientific Officer of Scholar Rock Corp since 2016. There are 1 older and 12 younger executives at Scholar Rock Corp. The oldest executive at Scholar Rock Holding Corp is Michael Gilman, 65, who is the Independent Director.
What's Alan Buckler's mailing address?
Alan's mailing address filed with the SEC is 620 MEMORIAL DRIVE, SECOND FLOOR, , CAMBRIDGE, MA, 02139.
Insiders trading at Scholar Rock Corp
Over the last 6 years, insiders at Scholar Rock Corp have traded over $8,613,447 worth of Scholar Rock Corp stock and bought 8,895,194 units worth $64,726,758 . The most active insiders traders include Timothy A Springer, Srinivas Akkaraju и Amir Nashat. On average, Scholar Rock Corp executives and independent directors trade stock every 55 days with the average trade being worth of $1,953,616. The most recent stock trade was executed by Caryn Parlavecchio on 16 August 2024, trading 1,451 units of SRRK stock currently worth $13,538.
What does Scholar Rock Corp do?
scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s
What does Scholar Rock Corp's logo look like?
Scholar Rock Corp executives and stock owners
Scholar Rock Corp executives and other stock owners filed with the SEC include:
-
Dr. Nagesh K. Mahanthappa MBA, Ph.D.,
Interim CEO & Director -
Yung Chyung,
Chief Medical Officer -
Alan Buckler,
Chief Scientific Officer -
Edward H. Myles M.B.A., MBA,
CFO & Head of Bus. Operations -
Dr. Gregory John Carven Ph.D.,
Chief Scientific Officer -
David Hallal,
Independent Chairman of the Board -
Michael Gilman,
Independent Director -
Kristina Burow,
Independent Director -
Edward Myles,
Chief Financial Officer -
Tony Kingsley,
President, Chief Executive Officer, Director -
Erin Moore,
Senior Vice President - Finance -
Catherine Hu,
IR Contact Officer -
Ryan Iarrobino,
Sr. VP of Clinical Devel. & Operations -
Erin Moore,
Sr. VP of Fin. -
Dr. George G. Nomikos M.D., Ph.D.,
Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic Area -
Lisa Amaya Price,
Sr. VP of HR -
Dr. Yung H. Chyung M.D.,
Chief Medical Officer -
Caryn Parlavecchio,
Chief HR Officer -
Junlin Ho J.D.,
Gen. Counsel & Corp. Sec. -
Public Equities, L.P.Artal ...,
-
Stuart A Kingsley,
President and CEO -
Richard Brudnick,
-
Bio Capital Gp, Llc Samsara...,
-
Srinivas Akkaraju,
-
Venture Management Co. Vi, ...,
-
Rhonda M. Chicko,
Chief Financial Officer -
Elan Ezickson,
COO & Head of Corp.Development -
Venture Fund Viii, L.P.Arch...,
-
International S.C.A.Invus P...,
-
Jeffrey S. Flier,
-
Katie Peng,
-
Jay T. Backstrom,
CHIEF EXECUTIVE OFFICER -
Timothy A Springer,
10% owner -
Mo Qatanani,
CHIEF SCIENTIFIC OFFICER -
Tracey Sacco,
CHIEF COMMERCIAL OFFICER -
Jing L. Marantz,
CHIEF MEDICAL OFFICER -
Joshua Reed,
-
Akshay Vaishnaw,
-
Gregory John Carven,
Chief Scientific Officer -
Amir Nashat,
-
Nagesh K. Mahanthappa,
Interim CEO and President -
Public Equities, L.P.Artal ...,
-
Junlin Ho,
GENERAL COUNSEL -
Caryn Parlavecchio,
CHRO